CytomX Therapeutics (NASDAQ: CTMX) reported Q1 EPS of $0.27, $0.21 better than the analyst estimate of $0.06. Revenue for the quarter came in at $50.92 million versus the consensus estimate of $29.7 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.